

DAFTAR PUSTAKA

- Aakeröy, C. B., Fasulo, M., Schultheiss, N., Desper, J., & Moore, C. (2007). Structural competition between hydrogen bonds and halogen bonds. *Journal of the American Chemical Society*, *129*(45), 13772–13773.
- Abifadel, M., Rabès, J. P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009). Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. *Human Mutation*, *30*(4), 520–529.
- Abifadel, M., Varret, M., Rabès, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., ... Boileau, C. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nature Genetics*, *34*(2), 154–156.
- Abramov, Y., Loschen, C., & KLAMT, A. (2012). Rational Coformer or Solvent Selection for Pharmaceutical Cocrystallization or Desolvation. *Journal of Pharmaceutical Sciences*, *101*(10), 1–11.
- Aher, S., Dhupal, R., Mahadik, K., Paradkar, A., & York, P. (2010). Ultrasound assisted cocrystallization from solution (USSC) containing a non-congruently soluble cocrystal component pair: Caffeine/maleic acid. *European Journal of Pharmaceutical Sciences*, *41*(5), 597–602.
- Aitipamula, S., Banerjee, R., Bansal, A. K., Biradha, K., Cheney, M. L., Choudhury, A. R., Desiraju, G. R., Dikundwar, A. G., Dubey, R., Duggirala, N., Ghogale, P. P., Ghosh, S., Goswami, P. K., Goud, N. R., Jetti, R. R. K. R., Karpinski, P., Kaushik, P., Kumar, D., Kumar, V., Zaworotko, M. J. (2012). Polymorphs, Salts, and Cocrystals: What's in a Name? *Crystal Growth & Design*, *12*(5), 2147–2152.
- Alhalaweh, A., & Velaga, S. P. (2010). Formation of cocrystals from stoichiometric solutions of incongruently saturating systems by spray drying. *Crystal Growth and Design*, *10*(8), 3302–3305.
- Almarsson, Ö., & Zaworotko, M. J. (2004). Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? *Chemical Communications*, *17*, 1889–1896.
- AOAC, 2019. *AOAC Guidelines for Single Laboratory Validation of Chemical Methods for Dietary Supplements and Botanicals*, 18-19, 24-25.
- Babu, N. J., & Nangia, A. (2011). Solubility advantage of amorphous drugs and pharmaceutical cocrystals. *Crystal Growth and Design*, *11*(7), 2662–2679.
- Badan Pengawas Obat dan Makanan Republik Indonesia. (2021). *Peraturan Badan*

Pengawas Obat dan Makanan Nomor 18 Tahun 2021 tentang Pedoman Uji Farmakodinamik Praklinik Obat Tradisional. Jakarta

- Bai, Y. F., & Xu, H. (2000). Protective action of piperine against experimental gastric ulcer. *Acta Pharmacologica Sinica*, 21(4), 357–359.
- Bajad, S., Coumar, M., Khajuria, R., Suri, O. P., & Bedi, K. L. (2003). Characterization of a new rat urinary metabolite of piperine by LC/NMR/MS studies. *European Journal of Pharmaceutical Sciences*, 19(5), 413–421.
- Ballantyne, C. M., Neutel, J., Cropp, A., Duggan, W., Wang, E. Q., Plowchalk, D., Sweeney, K., Kaila, N., Vincent, J., & Bays, H. (2015). Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. *American Journal of Cardiology*, 115(9), 1212–1221.
- Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., Greenfield, R. S., Hovingh, G. K., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P. M., Muntner, P., Goudev, A., Mikhailidis, D. P. (2015). Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Archives of Medical Science*, 11(1), 1–23.
- Bao, L., Bai, S., & Borijihan, G. (2012). Hypolipidemic effects of a new piperine derivative GB-N from Piper longum in high-fat diet-fed rats. *Pharmaceutical Biology*, 50(8), 962–967.
- Barter, P. J., & Rye, K. (2016). New Era of Lipid-Lowering Drugs. *The American Society For Pharmacology and Experimental Therapeutics*, 68(2), 458–475.
- Basavoju, S., Boström, D., & Velaga, S. P. (2008). Indomethacin-saccharin cocrystal: Design, synthesis and preliminary pharmaceutical characterization. *Pharmaceutical Research*, 25(3), 530–541.
- Batisai, E., Ayamine, A., Kilinkissa, O. E. Y., & Báthori, N. B. (2014). Melting point-solubility-structure correlations in multicomponent crystals containing fumaric or adipic acid. *CrystEngComm*, 16(43), 9992–9998.
- Bauer, J. E. (2004). Lipoprotein-mediated transport of dietary and synthesized lipids and lipid abnormalities of dog and cats. *Journal of the American Veterinary Medical Association*, 224(5), 668–675.
- Bayly, G. R. (2014). Lipids and disorders of lipoprotein metabolism. In *Clinical Biochemistry: Metabolic and Clinical Aspects: Third Edition* (Third Edit). Elsevier Ltd.
- Benjannet, S., Rhains, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M. C., Hamelin, J., Varret, M., Allard, D., Trillard, M., Abifadel, M., Tebon, A., Attie, A. D., Rader, D. J., Boileau, C., Brissette, L., Chrétien, M.,

- Prat, A., & Seidah, N. G. (2004). NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. *Journal of Biological Chemistry*, 279(47), 48865–48875.
- Benn, M., Nordestgaard, B. G., Grande, P., Schnohr, P., & Tybjaerg-Hansen, A. (2010). PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease. 3 Independent Studies and Meta-Analyses. *Journal of the American College of Cardiology*, 55(25), 2833–2842.
- Berry, D. J., & Steed, J. W. (2017). Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design. *Advanced Drug Delivery Reviews*, 117, 3–24.
- Bevill, M. J., Vlahova, P. I., & Smit, J. P. (2014). Polymorphic Cocrystals of Nutraceutical Compound p-Coumaric Acid with Nicotinamide: Characterization, Relative Solid-State Stability, and Conversion to Alternate Stoichiometries. *Crystal Growth & Design*, 14, 1438–1448.
- Bhogala, B. R., Basavoju, S., & Nangia, A. (2005). Tape and layer structures in cocrystals of some di- and tricarboxylic acids with 4,4'-bipyridines and isonicotinamide. From binary to ternary cocrystals. *CrystEngComm*, 7, 551–562.
- Bhusnure, O., Kazi, P., & Gholve, S. (2014). “Solid Dispersion : an Ever Green Method for Solubility Enhancement of Poorly Water Soluble Drugs.” *International Journal of Research in Pharmacy and Chemistry*, 4(4), 906–918.
- Bhusnure, O., Kazi, P., & Gholve, S. (2014). “Solid Dispersion : an Ever Green Method for Solubility Enhancement of Poorly Water Soluble Drugs.” *International Journal of Research in Pharmacy and Chemistry*, 4(4), 906–918.
- Blagden, N., de Matas, M., Gavan, P. T., & York, P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. *Advanced Drug Delivery Reviews*, 59(7), 617–630.
- Blagden, Nicholas, Berry, D. J., Parkin, A., Javed, H., Ibrahim, A., Gavan, P. T., De Matos, L. L., & Seaton, C. C. (2008). Current directions in co-crystal growth. *New Journal of Chemistry*, 32(10), 1659–1672.
- Boksa, K., Otte, A., & Pinal, R. (2014). Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion. *Journal of Pharmaceutical Sciences*, 103(9), 2904–2910.
- Bolla, G., & Nangia, A. (2016). Pharmaceutical cocrystals: Walking the talk. *Chemical Communications*, 52(54), 8342–8360.
- Brahmanaidu, P., Nemani, H., Meriga, B., Mehar, S. K., Potana, S., & Ramgopalrao, S. (2014). Mitigating efficacy of piperine in the physiological derangements of high fat diet induced obesity in Sprague Dawley rats. *Chemico-Biological Interactions*, 221, 42–51.
- Brittain, H. G. (1999). *Polymorphism in pharmaceutical solids*. New York: M.

Dekker. (Vol. 192).

- Buddhadev, S. S., & Garala, K. C. (2021). *Pharmaceutical Cocrystals—A Review*. 14.
- Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017). PCSK9: Regulation and target for drug development for dyslipidemia. *Annual Review of Pharmacology and Toxicology*, 57(July), 223–244. h
- Bysouth, S. R., Bis, J. A., & Igo, D. (2011). Cocrystallization via planetary milling: Enhancing throughput of solid-state screening methods. *International Journal of Pharmaceutics*, 411(1–2), 169–171.
- Cantarella, M., Cantarella, L., Gallifuoco, A., Intellini, R., Kaplan, O., Spera, A., & Martínková, L. (2008). Amidase-catalyzed production of nicotinic acid in batch and continuous stirred membrane reactors. *Enzyme and Microbial Technology*, 42(3), 222–229.
- Cao, F., Amidon, G. L., Rodriguez-Hornedo, N., & Amidon, G. E. (2016). Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization. *Molecular Pharmaceutics*, 13(3), 1030–1046.
- Careskey, H. E., Davis, R. A., Alborn, W. E., Troutt, J. S., Cao, G., & Konrad, R. J. (2008). Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. *Journal of Lipid Research*, 49(2), 394–398.
- Carlson, L. A. (2005). Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. *Journal of Internal Medicine*, 258(2), 94–114.
- Chaudhari, S., Nikam, S. A., Khatri, N., & Wakde, S. (2018). Co-Crystals: a Review. *Journal of Drug Delivery and Therapeutics*, 8(6-s), 350–358.
- Cherukuvada, S., & Row, T. N. G. (2014). Comprehending the Formation of Eutectics and Cocrystals in Terms of Design and Their Structural Interrelationships. *Crystal Growth & Design*. 14, 4187–4198.
- Chi, Z., Wang, M., Yang, L., Li, X., Cong, X., Liu, S., & Cai, B. (2013). Fourier Transform Near-Infrared Spectroscopy Used for Purity Determination of Rhein-L-arginine Cocrystal (Argirein). *Analytical Sciences*, 29(6), 661–664.
- Childs, S. L., Chyall, L. J., Dunlap, J. T., Smolenskaya, V. N., Stahly, B. C., & Stahly, G. P. (2004). Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. *Journal of the American Chemical Society*, 126(41), 13335–13342.
- Childs, S. L., Stahly, G. P., & Park, A. (2007). The salt-cocrystal continuum: The influence of crystal structure on ionization state. *Molecular Pharmaceutics*, 4(3), 323–338.

- Chopra, B., Dhingra, A. K., Kapoor, R. P., & Prasad, D. N. (2017). Piperine and Its Various Physicochemical and Biological Aspects: A Review. *Open Chemistry Journal*, 3(1), 75–96.
- Clarke, H. D. (2012). Crystal Engineering of Multi-Component Crystal Forms: The Opportunities and Challenges in Design. *ProQuest Dissertations and Theses*, January, 153.
- Cohen, J., Boerwinkle, E., Mosley, T., & Hobbs, H. (2011). Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. *The New Engl and Journal of Medicine*, 354(12), 1264–1272.
- Cunningham, D., Danley, D. E., Geoghegan, K. F., Griffor, M. C., Hawkins, J. L., Subashi, T. A., Varghese, A. H., Ammirati, M. J., Culp, J. S., Hoth, L. R., Mansour, M. N., McGrath, K. M., Seddon, A. P., Shenolikar, S., Stutzman-Engwall, K. J., Warren, L. C., Xia, D., & Qiu, X. (2007). Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. *Nature Structural and Molecular Biology*, 14(5), 413–419.
- Dai, X. L., Li, S., Chen, J. M., & Lu, T. B. (2016). Improving the Membrane Permeability of 5-Fluorouracil via Cocrystallization. *Crystal Growth and Design*, 16(8), 4430–4438.
- Daurio, D., Medina, C., Saw, R., Nagapudi, K., & Alvarez-Núñez, F. (2011). Application of twin screw extrusion in the manufacture of cocrystals, part I: Four case studies. *Pharmaceutics*, 3(3), 582–600.
- Davignon, J., Dubuc, G., & Seidah, N. G. (2010). The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. *Current Atherosclerosis Reports*, 12(5), 308–315.
- de Almeida, A. C., Torquetti, C., Ferreira, P. O., Fernandes, R. P., dos Santos, E. C., Kogawa, A. C., & Caires, F. J. (2020). Cocrystals of ciprofloxacin with nicotinic and isonicotinic acids: Mechanochemical synthesis, characterization, thermal and solubility study. *Thermochimica Acta*, 685.
- De Castro-oros, I., Pocovi, M., & Civeira, F. (2010). The genetic basis of familial hypercholesterolemia : inheritance , linkage , and mutations. *The Application of Clinical Genetics*, 3, 53–64.
- Desiraju, G. R. (2005). The Supramolecular Synthon in Crystal Engineering. *Stimulating Concepts in Chemistry*, 293–306.
- Desiraju, G. R. (2013). Crystal engineering: From molecule to crystal. *Journal of the American Chemical Society*, 135(27), 9952–9967.
- Dogra, R. K. S., Khanna, S., & Shanker, R. (2004). Immunotoxicological effects of

- piperine in mice. *Toxicology*, 196(3), 229–236.
- Dong, B., Wu, M., Li, H., Kraemer, F. B., Adeli, K., Seidah, N. G., Park, S. W., & Liu, J. (2010). Strong induction of PCSK9 gene expression through HNF1 α and SREBP2: Mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. *Journal of Lipid Research*, 51(6), 1486–1495.
- Duangjai, A., Ingkaninan, K., Praputbut, S., & Limpeanchob, N. (2013). Black pepper and piperine reduce cholesterol uptake and enhance translocation of cholesterol transporter proteins. *Journal of Natural Medicines*, 67(2), 303–310.
- Duggirala, N. K., Perry, M. L., Almarsson, Ö., & Zaworotko, M. J. (2016). Pharmaceutical cocrystals: Along the path to improved medicines. *Chemical Communications*, 52(4), 640–655.
- Eaton, C. B. (2005). Hyperlipidemia. *Primary Care - Clinics in Office Practice*, 32(4), 1027–1055.
- Feingold, K.R. (2021). Lipid and lipoprotein metabolism. *Endocrinology Metabolism Clinic North America*, 51(3):437-458.
- Fitriani, L., Afriyanti, I., Afriyani, Ismed, F., & Zaini, E. (2018). Solid dispersion of usnic acid–HPMC 2910 prepared by spray drying and freeze drying techniques. *Oriental Journal of Chemistry*, 34(4), 2083–2088.
- Fox, K. M., Tai, M. H., Kostev, K., Hatz, M., Qian, Y., & Laufs, U. (2018). Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. *Clinical Research in Cardiology*, 107(5), 380–388.
- Gadade, D. D., & Pekamwar, S. S. (2016). Pharmaceutical cocrystals: Regulatory and strategic aspects, design and development. *Advanced Pharmaceutical Bulletin*, 6(4), 479–494.
- Ghosh, T., Juturu, T., Nagar, S. N., & Kamath, S. (2021). *Cocrystals of Modafinil-Nicotinic Acid: A Novel Cocrystal for Enhanced Bioavailability*. 12.
- Gille, A., Bodor, E. T., Ahmed, K., & Offermanns, S. (2008). Nicotinic acid: Pharmacological effects and mechanisms of action. *Annual Review of Pharmacology and Toxicology*, 48, 79–106.
- Goldstein, J., Hobbs, H., & Brown, M. (2001). Familial Hypercholesterolemia. In CR Scriver, A. Beaudet, W. Sly, & D. Valle (Eds.), *The Metabolic and Molecular Basis of Inherited Disease*. 2863–2913. McGraw-Hill, New York.
- Gonçalves, E. M., Bernardes, C. E. S., Diogo, H. P., & Minas Da Piedade, M. E. (2010). Energetics and structure of nicotinic acid (Niacin). *Journal of Physical Chemistry B*, 114(16), 5475–5485.

- Good, D. J., & Rodríguez-Hornedo, N. (2010). Cocrystal Eutectic Constants and Prediction of Solubility Behavior. *Crystal Growth & Design*, 10(3), 1028–1032. <https://doi.org/10.1021/cg901232h>
- Goodman & Gilman's. (2008). Manual of Pharmacology and Therapeutics. In L. L. Brunton & K. L. Parker (Eds.), *The Lancet* (Vol. 117, Issue 2993). The McGraw-Hill Companies.
- Gorgani, L., Mohammadi, M., Najafpour, G. D., & Nikzad, M. (2017). Piperine—The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. *Comprehensive Reviews in Food Science and Food Safety*, 16(1), 124–140.
- Groom, C. R., & Allen, F. H. (2014). The Cambridge Structural Database in retrospect and prospect. *Angewandte Chemie - International Edition*, 53(3), 662–671.
- Grossjohann, C., Serrano, D. R., Paluch, K. J., O'Connell, P., Vella-Zarb, L., Manesiotis, P., McCabe, T., Tajber, L., Corrigan, O. I., & Healy, A. M. (2015). Polymorphism in Sulfadimidine/4-Aminosalicylic Acid Cocrystals: Solid-State Characterization and Physicochemical Properties. *Journal of Pharmaceutical Sciences*, 104(4), 1385–1398.
- Grothe, E., Meekes, H., Vlieg, E., Ter Horst, J. H., & De Gelder, R. (2016). Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification System. *Crystal Growth and Design*, 16(6), 3237–3243.
- Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007). Molecular biology of PCSK9: its role in LDL metabolism. *Trends in Biochemical Sciences*, 32(2), 71–77.
- Hou, X., Zhang, C., Wang, L., & Wang, K. (2021). Natural Piperine Improves Lipid Metabolic Profile of High-Fat Diet-Fed Mice by Upregulating SR-B1 and ABCG8 Transporters. *Journal of Natural Products*, 84(2), 373–381.
- Huang, S., Henry, L., Ho, Y. K., Pownall, H. J., & Rudenko, G. (2010). Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor. *Journal of Lipid Research*, 51(2), 297–308.
- Hyun, J. J., Lee, H. S., Kim, K. S., Kim, Y. K., Yoon, D., & Sahng, W. P. (2008). Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. *Journal of Lipid Research*, 49(2), 399–409.
- Infantes, L., & Motherwell, W. D. S. (2004). The probable number of hydrogen-bonded contacts for chemical groups in organic crystal structures. *Chemical Communications*, 4(10), 1166–1167.
- Jeon, H., Meng, W., Takagi, J., Eck, M. J., Springer, T. A., & Blacklow, S. C.

- (2001). letters Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. *Nature Structural Biology*, 8(6), 499–504.
- Jessica, A., Naura, R., Hasanah, U., Zaini, E., & Fitriani, L. (2021). Pembentukan Multikomponen Kristal Piperin Dan Kuersetin. *JOPS (Journal Of Pharmacy and Science)*, 4(2), 1–11.
- Jia, Y. J., Xu, R. X., Sun, J., Tang, Y., & Li, J. J. (2014). Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. *Journal of Translational Medicine*, 12(1), 1–8.
- Jiang, L., Huang, Y., Zhang, Q., He, H., Xu, Y., & Mei, X. (2014). Preparation and solid-state characterization of dapson drug-drug co-crystals. *Crystal Growth and Design*, 14(9), 4562–4573.
- Karam, I., Yang, Y. J., & Li, J. Y. (2017). SM Gr up SM Atherosclerosis Hyperlipidemia Background and Progress. *SM Atherosclerosis Journal*, 1(1), 9–15.
- Kalra, A., Yetiskul, E., Wehrle, C.J., & Tuma, F. (2022). *Physiology Liver*. Michigan: Stat Pearls Publishing.
- Karki, S., Friščić, T., Jones, W., & Motherwell, W. D. S. (2007). Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. *Molecular Pharmaceutics*, 4(3), 347–354.
- Karr, S. (2017). Epidemiology and management of hyperlipidemia. *The American Journal of Managed Care*, 23(9), S139–S148.
- Kementerian Kesehatan Republik Indonesia. (2017). *Farmakope Herbal Indonesia* (Edisi II). Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kim KJ, Lee MS, Jo K and Hwang JK (2011). Piperidine alkaloids from *Piper retrofractum* Vahl: Protect against high-fat diet-induced obesity by regulating lipid metabolism and activating AMP-activated protein kinase. *Biochem. Biophys. Res. Commun.*, 41(1): 219-225
- Korotkova, E. I., & Kratochvíl, B. (2014). Pharmaceutical Cocrystals. *Procedia Chemistry*, 10, 473–476.
- Kuiper, J. G., Sanchez, R. J., Houben, E., Heintjes, E. M., Penning-van Beest, F. J. A., Khan, I., van Riemsdijk, M., & Herings, R. M. C. (2017). Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. *Clinical Therapeutics*, 39(4), 1–9.
- Latimer, J., Batty, J. A., Neely, R. D. G., & Kunadian, V. (2016). PCSK9 inhibitors in the prevention of cardiovascular disease. *Journal of Thrombosis and Thrombolysis*, 42(3), 405–419.

- Lee and Wang. (2010). Screening, Manufacturing, Photoluminescence, and Molecular Recognition of Co-Crystals: Cytosine with Dicarboxylic Acids. *Crystal Growth and Design*, 10(3), 1419–1434.
- Leren, T. P. (2014). Sorting an LDL receptor with bound PCSK9 to intracellular degradation. *Atherosclerosis*, 237(1), 76–81.
- Li, J., Liu, P., Liu, J. P., Zhang, W. L., Yang, J. K., & Fan, Y. Q. (2012). Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: In vitro and in vivo evaluation. *European Journal of Pharmaceutics and Biopharmaceutics*, 80(2), 426–432.
- Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. *Journal of Pharmacological and Toxicological Methods*, 44(1), 235–249.
- Maheshwari, C., André, V., Reddy, S., Roy, L., Duarte, T., & Rodríguez-Hornedo, N. (2012). Tailoring aqueous solubility of a highly soluble compound via cocrystallization: Effect of cofomer ionization, pH max and solute-solvent interactions. *Cryst Eng Comm*, 14(14), 4801–4811.
- Majumder, M., Buckton, G., Rawlinson-Malone, C. F., Williams, A. C., Spillman, M. J., Pidcock, E., & Shankland, K. (2013). Application of hydrogen-bond propensity calculations to an indomethacin-nicotinamide (1 : 1) co-crystal. *CrystEngComm*, 15(20), 4041–4044.
- Mamuaja, C. F. (2017). Lipida. *Unsrat Press*, 1(1), 1–119.
- Maneesai, P., Scholfield, C., & Chootip, K. (2012). Piperine is Anti-hyperlipidemic and Improves Endothelium-Dependent Vasorelaxation in Rats on a High Cholesterol Diet. *Journal of Physiological and Biomedical Sciences*, 25(1), 327–330.
- Marduel, M., Carrié, A., Sassolas, A., Devillers, M., Carreau, V., Di Filippo, M., Erlich, D., Abifadel, M., Marques-Pinheiro, A., Munnich, A., Junien, C., Boileau, C., Varret, M., & Rabès, J. P. (2010). Molecular spectrum of autosomal dominant hypercholesterolemia in France. *Human Mutation*, 31(11), 1811–1824.
- Maxwell, K. N., & Breslow, J. L. (2004). Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, 101(18), 7100–7105.
- Mohammad, M. A., Alhalaweh, A., & Velaga, S. P. (2011). Hansen solubility parameter as a tool to predict cocrystal formation. *International Journal of Pharmaceutics*, 407(1–2), 63–71.
- Mukaida, M., Watanabe, Y., Sugano, K., & Terada, K. (2015). Identification and physicochemical characterization of caffeine-citric acid co-crystal

polymorphs. *European Journal of Pharmaceutical Sciences*, 79, 61–66.

- Nassoury, N., Blasiolo, D. A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V., McPherson, P. S., Attie, A. D., Prat, A., & Seidah, N. G. (2007). The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLr. *Traffic*, 8(6), 718–732.
- Nawale, S., Padma Priya, K., Pranusha, P., & Ganga Raju, M. (2018). Data of antihyperlipidaemic activity for methanolic extract of *Tagetes patula* Linn. flower head along with piperine, as bioavailability enhancer. *Data in Brief*, 21, 587–597.
- Ochiai, A., Miyata, S., Shimizu, M., Inoue, J., & Sato, R. (2015). Piperine induces hepatic low-density lipoprotein receptor expression through proteolytic activation of sterol regulatory element-binding proteins. *PLoS ONE*, 10(10), 1–15.
- Octavia, M. D., Halim, A., & Zaini, E. (2015). Preparation of Simvastatin- β -Cyclodextrin inclusion complexes using coevaporation technique.pdf. *Journal of Chemical and Pharmaceutical Research*, 7(2), 740–747.
- Pachauri, M., Gupta, E. D., & Ghosh, P. C. (2015). Piperine loaded PEG-PLGA nanoparticles: Preparation, characterization and targeted delivery for adjuvant breast cancer chemotherapy. *Journal of Drug Delivery Science and Technology*, 29, 269–282.
- Padrela, L., Rodrigues, M. A., Velaga, S. P., Fernandes, A. C., Matos, H. A., & de Azevedo, E. G. (2010). Screening for pharmaceutical cocrystals using the supercritical fluid enhanced atomization process. *Journal of Supercritical Fluids*, 53(1–3), 156–164.
- Parthasarathy, V. A., Chempakam, B., & Zachariah, T. J. (2008). Chemistry of spices. In *Chemistry of Spices*.
- Parvez Md., S.Mounika, M. G., Sudha, R. K., Sumayya, S., & Soumya. (2013). Effect of ethanolic extract of *Piper nigrum* Linn. fruits on pharmacodynamics of atorvastatin in rats. *International Journal of Research in Pharmacology & Pharmacotherapeutics*, 2(1), 242–247.
- Patel, D. J., & Puranik, P. K. (2020). Pharmaceutical Co-crystal : An Emerging Technique to enhance Physicochemical properties of drugs. *International Journal of ChemTech Research*, 13(3), 283–290.
- Patil UK, Singh A, Chakraborty AK. 2011. Role of piperine as a bioavailability enhancer. *Int J Recent Adv Pharmac Res* 4:16–23.
- Peterson, M. L., Collier, E. A., Hickey, M. B., Guzman, H., & Almarsson, Ö. (2010). Multi-Component Pharmaceutical Crystalline Phases: Engineering for Performance. In *Organic Crystal Engineering: Frontiers in Crystal Engineering*.

- Pfund, L. Y., Chamberlin, B. L., & Matzger, A. J. (2015). The bioenhancer piperine is at least trimorphic. *Crystal Growth and Design*, 15(5), 2047–2051. <https://doi.org/10.1021/acs.cgd.5b00278>
- Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. *European Journal of Pharmaceutical Sciences*, 29(3-4 SPEC. ISS.), 278–287.
- Prasad, R. V., Rakesh, M. G., Jyotsna, R. M., Mangesh, S. T., Sapkale, P., & Mayur, P. K. (2012). *Pharmaceutical Cocrystallization : A Review*. 1(3), 1074–1085.
- Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., & Trappitt, G. (2011). Pharmaceutical cocrystals: An overview. *International Journal of Pharmaceutics*, 419(1–2), 1–11.
- Raman, G., & Gaikar, V. G. (2002). Microwave-assisted extraction of piperine from *Piper nigrum*. *Industrial and Engineering Chemistry Research*, 41(10), 2521–2528.
- Rathod, S. S., & Rathod, V. K. (2014). Extraction of piperine from *Piper longum* using ultrasound. *Industrial Crops and Products*, 58, 259–264.
- Reckless, J. P. D., & Lawrence, J. M. (2003). Hyperlipidemia (Hyperlipidaemia). *Encyclopedia of Food Sciences and Nutrition*, 3183–3192.
- Ren, T., Hu, M., Cheng, Y., Shek, T. L., Xiao, M., Ho, N. J., Zhang, C., Leung, S. S. Y., & Zuo, Z. (2019). Piperine-loaded nanoparticles with enhanced dissolution and oral bioavailability for epilepsy control. *European Journal of Pharmaceutical Sciences*, 137(May), 104988.
- Rodríguez-Spong, B., Price, C. P., Jayasankar, A., Matzger, A. J., & Rodríguez-Hornedo, N. (2004). General principles of pharmaceutical solid polymorphism: A supramolecular perspective. *Advanced Drug Delivery Reviews*, 56(3), 241–274.
- Ross, S. A., Lamprou, D. A., & Douroumis, D. (2016). Engineering and manufacturing of pharmaceutical co-crystals: A review of solvent-free manufacturing technologies. *Chemical Communications*, 52(57), 8772–8786.
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A. (2015). Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. *New England Journal of Medicine*, 372(16), 1500–1509.
- Sabina EP, Souriyana ADH, Jackline D, Rasool MK. 2010. Piperine, an active ingredient of black pepper attenuates acetaminophen-induced hepatotoxicity in mice. *Asian Pac J Trop Dis* 3:971–6
- Sahng, W. P., Moon, Y. A., & Horton, J. D. (2004). Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase

- subtilisin/kexin type 9a in mouse liver. *Journal of Biological Chemistry*, 279(48), 50630–50638.
- Sanphui, P., Devi, V. K., Clara, D., Malviya, N., Ganguly, S., & Desiraju, G. R. (2015). Cocrystals of hydrochlorothiazide: Solubility and diffusion/permeability enhancements through drug-coformer interactions. *Molecular Pharmaceutics*, 12(5), 1615–1622.
- Sari, Y. N., Zaini, E., & Ismed, F. (2019). Peningkatan laju disolusi piperine dengan pembentukan multikomponen kristal menggunakan asam nikotinat. *Jurnal Sains Farmasi & Klinis* 6(2), 180.
- Sarma, B., Chen, J., Hsi, H. Y., & Myerson, A. S. (2011). Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals. *Korean Journal of Chemical Engineering*, 28(2), 315–322.
- Sarnaizul, E., Borjihhan, G., & Zhaorigetu, S. (2012). The preparation and antihyperlipidaemic assay of piperlonguminine in vivo. *Phytochemistry Letters*, 1–5.
- Sathali, A. A. H., & Selvaraj, V. (2012). *Enhancement of Solubility and Dissolution Rate of Racecadotril By Solid Dispersion Methods*. 2(3), 209–225.
- Sathisaran, I., & Dalvi, S. V. (2018). Engineering cocrystals of poorly water-soluble drugs to enhance dissolution in aqueous medium. *Pharmaceutics*, 10(3), 58–74.
- Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018). Novel Therapeutic Targets for Managing Dyslipidemia. *Trends in Pharmacological Sciences*, 39(8), 733–747.
- Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug Solubility: Importance and Enhancement Techniques. *ISRN Pharmaceutics*, 2012, 1–10.
- Schultheiss, N., & Newman, A. (2009). Pharmaceutical cocrystals and their physicochemical properties. *Crystal Growth and Design*, 9(6), 2950–2967.
- Schulz, R., Schlüter, K. D., & Laufs, U. (2015). Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). *Basic Research in Cardiology*, 110(2).
- Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Bélanger Jasmin, S., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003). The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, 100(3), 928–933.
- Seidah, N. G., & Prat, A. (2012). The biology and therapeutic targeting of the proprotein convertases. *Nature Reviews Drug Discovery*, 11(5), 367–383.

- Sekhon, B. (2009). Pharmaceutical co-crystals - a review. *ARS Pharmaceutica*, 50(3), 99–117.
- Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility. *Advanced Drug Delivery Reviews*, 59(7), 603–616.
- Serrano, D. R., O'Connell, P., Paluch, K. J., Walsh, D., & Healy, A. M. (2016). Cocrystal habit engineering to improve drug dissolution and alter derived powder properties. *Journal of Pharmacy and Pharmacology*, 68(5), 665–677.
- Setyawan, D., dan Zaini, E. (2018). Polimorf Bahan Aktif Farmasi. Airlangga University Press.
- Shan, N., Toda, F., & Jones, W. (2002). Mechanochemistry and co-crystal formation: Effect of solvent on reaction kinetics. *Chemical Communications*, 2(20), 2372–2373.
- Shattat, G. F. (2014). A review article on hyperlipidemia: Types, treatments and new drug targets. *Biomedical and Pharmacology Journal*, 7(2), 399–409.
- Sinko, P., & Singh, Y. (2011). *Martin's physical pharmacy and pharmaceutical sciences. Physical Chemical and Biopharmaceutical Principles in the Pharmaceutical Sciences Editor* (D. B. Troy (Ed.); Sxth Editi). Lippincott Williams & Wilkins, a Wolters Kluwer business.
- Sopyan, I., Fudholi, A., Muchtaridi, M., & Sari, I. P. (2017). Simvastatin-nicotinamide co-crystal: Design, preparation and preliminary characterization. *Tropical Journal of Pharmaceutical Research*, 16(2), 297–303. <https://doi.org/10.4314/tjpr.v16i2.6>
- Steed, J. W. (2013). The role of co-crystals in pharmaceutical design. *Trends in Pharmacological Sciences*, 34(3), 185–193.
- Stoler, E., & Warner, J. C. (2015). Non-Covalent derivatives: Cocrystals and eutectics. *Molecules*, 20(8), 14833–14848.
- Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021). Pcsk9: A multi-faceted protein that is involved in cardiovascular biology. *Biomedicines*, 9(7), 1–22.
- Sunila E, Kuttan G. 2004. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine. *J Ethnopharmacol* 90:339–46
- Surampalli, G., Nanjwade, B. K., Patil, P. A., & Chilla, R. (2016). Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. *Drug Delivery*, 23(7), 2124–2138.
- Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., & Amidon, G. L. (2006). A provisional biopharmaceutical classification of the top 200 oral

- drug products in the United States, Great Britain, Spain, and Japan. *Molecular Pharmaceutics*, 3(6), 631–643.
- Tasleem, F., Azhar, I., Ali, S. N., Perveen, S., & Mahmood, Z. A. (2014). Analgesic and anti-inflammatory activities of *Piper nigrum* L. *Asian Pacific Journal of Tropical Medicine*, 7(S1), S461–S468.
- Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013). Pharmaceutical cocrystals and poorly soluble drugs. *International Journal of Pharmaceutics*, 453(1), 101–125.
- Thipparaboina, R., Kumar, D., Chavan, R. B., & Shastri, N. R. (2016). Multidrug co-crystals: Towards the development of effective therapeutic hybrids. *Drug Discovery Today*, 21(3), 481–490.
- Tibolla, G., Norata, G. D., Artali, R., Meneghetti, F., & Catapano, A. L. (2011). Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition. *Nutrition, Metabolism and Cardiovascular Diseases*, 21(11), 835–843.
- Trivedi, M. K., Branton, A., Trivedi, D., Nayak, G., Bairwa, K., Jana, S., Trivedi, M. K., Branton, A., Trivedi, D., Nayak, G., & Bairwa, K. (2016). Spectroscopic Characterization of Disulfiram and Nicotinic Acid after Biofield Treatment. *Journal of Analytical & Bioanalytical Techniques*. 6(5). 1–5.
- Vijayakumar, R. S., Surya, D., & Nalini, N. (2004). Antioxidant efficacy of black pepper (*Piper nigrum* L.) and piperine in rats with high fat diet induced oxidative stress. *Redox Report*, 9(2), 105–110.
- Vasavirama, K., & Upender, M. (2014). Piperine: A valuable alkaloid from piper species. *International Journal of Pharmacy and Pharmaceutical Sciences*, 6(4), 34–38.
- Vishweshwar, P., McMahon, J. A., Bis, J. A., & Zaworotko, M. J. (2006). Pharmaceutical co-crystals. *Journal of Pharmaceutical Sciences*, 95(3), 499–516.
- Vogel, G. (2002). *Drug Discovery and Evaluation Pharmacological Assays Second Edition, Human & Experimental Toxicology*.
- Wahyudiati, D. (2017). *Biokimia* (J. Edi M (ed.); I). LEPPIM Mataram.
- Watts, G. F., Gidding, S., Wierzbicki, A. S., Toth, P. P., Alonso, R., Brown, W. V., Bruckert, E., Defesche, J., Lin, K. K., Livingston, M., Mata, P., Parhofer, K. G., Raal, F. J., Santos, R. D., Sijbrands, E. J. G., Simpson, W. G., Sullivan, D. R., Susekov, A. V., Tomlinson, B., Kastelein, J. J. P. (2014). Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *International Journal of Cardiology*, 171(3), 309–325.
- Welder, G., Zineh, I., Pacanowski, M. A., Troutt, J. S., Cao, G., & Konrad, R. J.

- (2010). High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. *Journal of Lipid Research*, 51(9), 2714–2721.
- Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013). Strategies to address low drug solubility in discovery and development. *Pharmacological Reviews*, v. 65, n. 1, p. 315–499, 2013. *Pharmacological Reviews*, 65(1), 315–499.
- Xenoulis, P. G., & Steiner, J. M. (2010). Lipid metabolism and hyperlipidemia in dogs. *Veterinary Journal*, 183(1), 12–21.
- Xu, R. X., Liu, J., Li, X. L., Li, S., Zhang, Y., Jia, Y. J., Sun, J., & Li, J. J. (2015). Impacts of ezetimibe on PCSK9 in rats: Study on the expression in different organs and the potential mechanisms. *Journal of Translational Medicine*, 13(1), 1–7.
- Yadav, S., Gupta, P. C., Sharma, N., & Kumar, J. (2015). Cocrystals: An Alternative Approach To Modify Physicochemical Properties of Drugs. *International Journal of Pharmaceutical, Chemical and Biological Sciences*, 5(2), 427–436.
- Yuliandra, Y., Zaini, E., Syofyan, S., Pratiwi, W., Putri, L. N., Pratiwi, Y. S., & Arifin, H. (2018). Cocrystal of ibuprofen–nicotinamide: Solid-state characterization and in vivo analgesic activity evaluation. *Scientia Pharmaceutica*, 86(2), 1–11.
- Zaid, A., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Chamberland, A., Hamelin, J., Tremblay, M., Jacques, H., Jin, W., Davignon, J., Seidah, N. G., & Prat, A. (2008). Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. *Hepatology*, 48(2), 646–654.
- Zaini, E., Afriyani, Fitriani, L., Ismed, F., Horikawa, A., & Uekusa, H. (2020). Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Scientia Pharmaceutica*, 88(2).
- Zaini, E., Riska, D., Oktavia, M. D., Ismed, F., & Fitriani, L. (2020). Improving dissolution rate of piperine by multicomponent crystal formation with saccharin. *Research Journal of Pharmacy and Technology*, 13(4), 1926–1930.
- Zaini, E., Fitriani, L., Sari, R. Y., Rosaini, H., Horikawa, A., & Uekusa, H. (2019). Multicomponent Crystal of Mefenamic Acid and N-Methyl-D-Glucamine: Crystal Structures and Dissolution Study. *Journal of Pharmaceutical Sciences*, 108(7), 2341–2348.
- Zaini, E., Sumirtapura, Y. C., Halim, A., Fitriani, L., & Soewandhi, S. N. (2017). Formation and characterization of sulfamethoxazole-trimethoprim cocrystal by milling process. *Journal of Applied Pharmaceutical Science*, 7(12), 169–173.

- Zhang, D. W., Lagace, T. A., Garuti, R., Zhao, Z., McDonal, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007). Binding of Proprotein Convertase Subtilisin / Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. *The Journal of Biological Chemistry*, 282(25), 18602–18612.
- Zhang, Y., Ma, K. L., Ruan, X. Z., & Liu, B. C. (2016). Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury. *International Journal of Biological Sciences*, 12(5), 569–579.
- Zhou, Z., Li, W., Sun, W. J., Lu, T., Tong, H. H. Y., Sun, C. C., & Zheng, Y. (2016). Resveratrol cocrystals with enhanced solubility and tableability. *International Journal of Pharmaceutics*, 509(1–2), 391–399.

